International validation of the Metabolic Exercise test data combined with Cardiac and Kidney Indexes (MECKI) score in heart failure.

Autor:	Adamopoulos S; Heart Failure and Heart Transplant Units, Onassis Cardiac Surgery Centre, Leof. Andrea Siggrou 356, Kallithea, 176 74, Attica, Greece., Miliopoulos D; Heart Failure and Heart Transplant Units, Onassis Cardiac Surgery Centre, Leof. Andrea Siggrou 356, Kallithea, 176 74, Attica, Greece., Piotrowicz E; Telecardiology Center, National Institute of Cardiology, Alpejska 42, 04-628 Warszawa, Poland., Snoek JA; Department of Sports Medicine and Cardiology, Dokter Van Heesweg 2, 8025 AB Zwolle, Netherlands., Panagopoulou N; Department of Cardiology, 'Helena Venizelou' Hospital, Elenas Venizelou 2, Athina 115 21, Greece., Nanas S; Department of ICU, 'Evangelismos' Hospital, Ipsilantou 45-47, Athina 106 76, Greece., Niederseer D; Department of Cardiology, University Heart Center Zurich, University of Zurich, Rämistrasse 100, 8091 Zürich, Switzerland., Mazaheri R; Department of Cardiology, University Heart Center Zurich, University of Zurich, Rämistrasse 100, 8091 Zürich, Switzerland., Ma J; Department of Cardiology, First Medical Center of PLA General Hospital, 28 Fuxing Road, 100853 Beijing, China., Chen Y; Department of Cardiology, Sixth Medical Center of PLA General Hospital, 6 Fucheng Road, Beijing, Cina, 100053., Popovic D; Department of Cardiology, Clinical Center of Serbia, University Clinical Center of Serbia, Pasterova 2, 11000 BelgradE, Serbia.; Department of Cardiovascular Medicine, Mayo Clinic, 200 First street SW, Rochester, MN 55905, USA., Seferovic P; Department of Cardiology, Clinical Center of Serbia, University Clinical Center of Serbia, Pasterova 2, 11000 BelgradE, Serbia., Girola D; Capo Clinica, Clinica Hildebrand, Centro di riabilitazione Brissago, Via Crodolo 18, 6614 Brissago, Switzerland., Corrà U; Istituti Clinici Maugeri, IRCCS, Via Revislate, 13 · 0322, Veruno, Italy., Coats AJS; Office of the CEO, Heart Research Institute, 7 Eliza St, Newtown NSW 2042, Sydney, Australia., Metra M; Cardiology, University of Brescia, Piazza del Mercato, 15, 25121, Brescia, Italy., Rosano GMC; Cardio-Pulmonary Department, IRCCS San Raffaele La Pisana, Via della Pisana, 235. 00163 Roma, Italy., Volterrani M; Cardio-Pulmonary Department, IRCCS San Raffaele La Pisana, Via della Pisana, 235. 00163 Roma, Italy., Apostolo A; Heart Failure Unit, Centro Cardiologico Monzino IRCCS, Via Parea 4, 20138, Milano, Italy., Campodonico J; Heart Failure Unit, Centro Cardiologico Monzino IRCCS, Via Parea 4, 20138, Milano, Italy., Salvioni E; Heart Failure Unit, Centro Cardiologico Monzino IRCCS, Via Parea 4, 20138, Milano, Italy., Agostoni P; Heart Failure Unit, Centro Cardiologico Monzino IRCCS, Via Parea 4, 20138, Milano, Italy.; Department of Clinical Sciences and Community Medicine, University of Milan, Via Festa del Perdono, 7, 20122 Milano, Italy., Piepoli M; Clinical Cardiology, IRCCS Policlinico San Donato, Via Morandi 30, 20097 Milan, Italy.; Department of Biomedical Sciences for Health, University of Milan, Via Festa del Perdono, 7, 20122 Milano, Italy.
Jazyk:	angličtina
Zdroj:	European journal of preventive cardiology [Eur J Prev Cardiol] 2023 Sep 20; Vol. 30 (13), pp. 1371-1379.
DOI:	10.1093/eurjpc/zwad191
Abstrakt:	Aims: Current European heart failure (HF) guidelines suggest the use of risk score: among them, the Metabolic Exercise test data combined with Cardiac and Kidney Indexes (MECKI) score has demonstrated to be one of the most accurate. However, the risk scores are still poorly implemented in clinical practice, also due to the lack of strong evidence regarding their external validation in different populations. Thus, the current study was designed as an external validation test of the MECKI score in an international multicentre setting. Methods and Results: The study cohort consisted of patients diagnosed with HF with reduced ejection fraction (HFrEF) across international centres (not Italian), retrospectively recruited. Collected data included demographics, HF aetiology, laboratory testing, electrocardiogram (ECG), echocardiographic findings, and cardiopulmonary exercise testing (CPET) results as described in the original MECKI score publication. A total of 1042 patients across 8 international centres (7 European and 1 Asian) were included and followed up from 1998 till 2019. Patients were divided according to the calculated MECKI scores into three subgroups: (i) MECKI score <10%, (ii) 10-20%, and (iii) ≥ 20%. Survival analysis comparison among the three MECKI score subgroups showed a worse prognosis in patients with higher MECKI score value: median event-free survival times were 4396 days for MECKI score <10%, 3457 days for 10-20%, and 1022 days for ≥20% (P < 0.0001). Receiver operating characteristic (ROC) curves and area under the ROC curves (AUC) were like those reported in the original internal validation studies. Conclusion: In patients diagnosed with HFrEF, the power of the MECKI score was confirmed in terms of prognosis and risk stratification, supporting its implementation as advised by the HF guidelines. Competing Interests: Conflict of interest: None related to the present manuscript. Giuseppe Rosano received support from Menarini, Servier, Boheringer Ingelheim, and AstraZeneca and is President of the Heart Failure Association. (© The Author(s) 2023. Published by Oxford University Press on behalf of the European Society of Cardiology.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu